SUBSCRIBE
SUBSCRIBE
News   Policy

NicOx SA Plans to Appeal U.S. Naproxcinod Refusal

February 24, 2011 | 
1 min read
PARIS, Feb 24 (Reuters) - French biotech NicOx (NCOX.PA) plans to appeal the decision of the U.S. health regulator to turn down its anti-inflammatory drug naproxcinod for marketing approval, the French biotech said on Thursday.
Regulatory Europe
MORE ON THIS TOPIC
Washington, D.C., USA- January 13, 2020: FDA Sign at its headquarters in Washington DC. The Food and Drug Administration (FDA or USFDA) is a federal agency of the USA.
FDA
FDA’s Hoeg Reportedly Trying To Hire Friend, Fellow Antidepressant Skeptic
March 5, 2026
 · 
2 min read
 · 
Tristan Manalac
Business decision concept with a businessman standing on a huge question mark. Symbol of the future, opportunities, planning, vision. Vector illustration
Regulatory
PepGen’s Mid-Stage Myotonic Dystrophy Study Hit With ‘Surprise’ Pause
March 5, 2026
 · 
2 min read
 · 
Tristan Manalac
Illustration of a yellow envelope on a blue background with a read warning symbol
Supply chain
FDA Sends 30 Warning Letters To Continue Clampdown on Compounded GLP-1s
March 4, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
 · 
1 min read
 · 
Heather McKenzie